key: cord-1054876-e2vpqhk9 authors: Piccolo, V.; Bassi, A.; Russo, T.; Mazzatenta, C.; Baraldi, M.; Argenziano, G.; Neri, I.; Cutrone, M. title: Chilblain‐like lesions and COVID‐19: second wave, second outbreak date: 2021-03-02 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17145 sha: 82c14e6fcfdfe8fdb122a9789cbc8685dcb297b8 doc_id: 1054876 cord_uid: e2vpqhk9 nan Chilblain-like lesions and COVID-19: second wave, second outbreak Dear Editor, During the first phase of European epidemic of COVID-19, a contemporary outbreak of chilblain-like lesions (CLL) has been reported. 1 After that, hundreds of similar cases have been described in the world. CLL typically appeared in young otherwise healthy patients with no proven SARS-CoV-2 infection, and most studies did not show positivity of PCR of serology. In Italy, during the trimester March-April-May we experienced the majority of cases of COVID-19 and contemporarily of CLL. [2] [3] [4] During summertime, a dramatic decrease of infected patients was observed, and in that context, CLL were not reported anymore. Unfortunately, a second wave of infections flooded Italy in September and Europe as well. With the fast increase of number of contagions, after a couple of months, novel cases of CLL have reappeared in Italy. We have collected further 15 cases ( Fig. 1 ) in different Italian regions. Patient's profile was the same as the first wave: asymptomatic adolescent (mean age: 14 years) with history of contact with positive patients, but negative swab or serology. Also, morphology of the lesions appeared identical with CLL mostly occurring on the feet (rarely hands) with erythematousoedematous or blistering lesions. Among these patients, one had a recurrence of CLL after lesions appeared in the first wave. It seems obvious to think that if the second wave is accompanied by a second outbreak of CLL, the relationship is certain. Actually, in most patients a direct or indirect presence of the infection has not been found. 5 This is the first description of the second wave, and cases of CLL are probably expected to increase again. The reason of this phenomenon is still unknown, but two different hypotheses could be advanced. The first and most accepted one supports a relationship with SARS-CoV-2 infection, whose contact would induce in young patients a higher innate more than cell-mediated immune response with consequent fast clearance of antibodies and appearance of CLL. [6] [7] [8] [9] [10] The second less likely hypothesis is due to immobility; indeed, in Italy the first outbreak was observed during the lockdown and the second outbreak is now occurring during the soft lockdown as well. Young guys are the most affected by these measures because they are not attending schools and spending most of their time sat down watching monitors or TV. The lack of mobility could create a decreased blood flow with consequent appearance of CLL. Although interesting, against this second hypothesis is that frostbite is not among the cutaneous signs observed in paraplegic or wheelchair-immobilized patients. We would like to share these new data about the second outbreak and need to wait what is going to happen in the next future in order to understand whether the Italian CLL will be followed by the rest of Europe. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Chilblain-like lesions during the COVID-19 pandemic: should we really worry? Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: Aa multicenter study on 10 patients Acral findings during the COVID-19 outbreak: Chilblain-like lesions should be preferred to acroischemic lesions Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic Negative SARS-CoV-2 PCR in patients with chilblain-like lesions Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections COVID-19 and outbreak of chilblains: are they related? Chilblain-like lesions during COVID-19 pandemic: the state of the art